|Toxiciy Grade:||4||City/State/Province:||Isehara, Kanagawa|
|Treatments:||Chemotherapy||Hospital:||Tokai University School of Medicine|
Patients: This phase III study involved 97 women with stage I to IIIB breast cancer. The median age was 46 years, and the majority (74%) of patients were premenopausal.
Treatment: All patients had mastectomy surgery, and then were treated with chemotherapy. The women received either ‘standard-dose’ treatment with cyclophosphamide, doxorubicin, fluorouracil, and tamoxifen, or ‘high-dose’ treatment with cyclophosphamide, thiotepa, doxorubicin, fluorouracil, and tamoxifen.
Toxicity: All patients treated with the high-dose had grade 4 neutropenia and leukopenia. Grade 4 diarrhea, elevated liver enzymes, and arrhythmia were also reported in this treatment groups. In the standard-dose group, 8% of patients developed grade 4 neutropenia. The most common non-hematological grade 3 toxicity was nausea/vomiting.
Results: The estimated median overall survival was 87 months for the standard-dose group and 110 months for the high-dose group.
Correspondence: Dr. Yutaka Tokuda